Dianthus Therapeutics Stock Current Liabilities
| DNTH Stock | 25.00 0.19 0.77% |
Dianthus Therapeutics fundamentals help investors to digest information that contributes to Dianthus Therapeutics' financial success or failures. It also enables traders to predict the movement of Dianthus Stock. The fundamental analysis module provides a way to measure Dianthus Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dianthus Therapeutics stock.
Dianthus |
Dianthus Therapeutics Company Current Liabilities Analysis
Dianthus Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Dianthus Therapeutics has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Dianthus Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dianthus Therapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dianthus Therapeutics could also be used in its relative valuation, which is a method of valuing Dianthus Therapeutics by comparing valuation metrics of similar companies.Dianthus Therapeutics is currently under evaluation in current liabilities category among its peers.
Dianthus Fundamentals
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (13.77) % | ||||
| Current Valuation | 441.06 M | ||||
| Shares Outstanding | 29.6 M | ||||
| Shares Owned By Insiders | 8.76 % | ||||
| Shares Owned By Institutions | 91.24 % | ||||
| Number Of Shares Shorted | 5.44 M | ||||
| Price To Book | 2.14 X | ||||
| Price To Sales | 133.81 X | ||||
| Revenue | 2.83 M | ||||
| Gross Profit | 6.42 M | ||||
| EBITDA | (48.17 M) | ||||
| Net Income | (43.55 M) | ||||
| Total Debt | 585 K | ||||
| Book Value Per Share | 11.51 X | ||||
| Cash Flow From Operations | (36.86 M) | ||||
| Short Ratio | 19.62 X | ||||
| Earnings Per Share | 7.22 X | ||||
| Target Price | 51.8 | ||||
| Number Of Employees | 53 | ||||
| Market Capitalization | 718.02 M | ||||
| Total Asset | 179.41 M | ||||
| Retained Earnings | (89.42 M) | ||||
| Working Capital | 167.82 M | ||||
| Net Asset | 179.41 M |
About Dianthus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dianthus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dianthus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dianthus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Dianthus Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dianthus Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dianthus Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dianthus Therapeutics Stock:Check out Dianthus Therapeutics Piotroski F Score and Dianthus Therapeutics Altman Z Score analysis. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.